PMPRB therapeutic evaluations and CDR/pCODR listing recommendations
| CDR/pCODR listing recommendation | Therapeutic evaluation by PMPRB | ||||
|---|---|---|---|---|---|
| Breakthrough or substantial improvement | Moderate improvement (2010 onward) | Moderate, little or no improvement (before 2010) | Slight or no improvement (2010 onward) | No evaluation | |
| List in formulary in a manner similar to other drugs in the same class | 0 | 0 | 1 | 0 | 0 |
| List subject to conditions | 1 | 1 | 4 | 4 | 2 |
| Do not list | 0 | 2 | 7 | 4* | 0 |
Note: CDR = Common Drug Review, pCODR = pan-Canadian Oncology Drug Review, PMPRB = Patented Medicine Prices Review Board.
↵* For 1 of these drugs, the recommendation was that the drug not be listed at the price submitted by the company.